BCL2 and B-cell chronic lymphocytic leukemia: Although Bcl-2 inhibitor venetoclax is highly effective in hematologic malignancies, especially in CLL, the acquired and intrinsic resistance still cause treatment failure (Ramsey et al. 2018).